1-4 of 4
Coleen Bejot, MSN
Close
Sort by
Journal Articles

Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant

Tatyana Feldman, MD, Anthony R Mato, MD, Michele L. Donato, MD, Scott D Rowley, MD, Stuart L. Goldberg, MD, Carolanne Carini, RN, Marisa Valentinetti, RN, Judith Smith, RN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Susan Stives, APN, Mary Timberg, RN, MSN, OCN, NP-C, Ewelina A Protomastro, BA, Joshua R. Richter, MD, David H. Vesole, MD, PhD, Andrew L Pecora, MD, David S. Siegel, MD, PhD, Andre Goy, MD
Journal: Blood
Blood (2012) 120 (21): 3710.
https://doi.org/10.1182/blood.V120.21.3710.3710
Published: 2012
Journal Articles

Dose-Intensive (R-HCVAD) and High Dose Therapy (ASCT) Frontline Strategies More Than Double PFS Over Standard Therapy in MCL Patients

Anthony R Mato, MD, Ewelina A Protomastro, BA, Tania Zielonka, RDC, Tatyana Feldman, MD, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Pritish K. Bhattacharyya, MD, Mary Timberg, RN, MSN, OCN, NP-C, Susan Stives, APN, Gabriella Gadaleta, RN, APN-C, Coleen Bejot, MSN, NP-C, Andre Goy, MD
Journal: Blood
Blood (2012) 120 (21): 3658.
https://doi.org/10.1182/blood.V120.21.3658.3658
Published: 2012
Journal Articles

Feasibility and Outcome of High Dose Therapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric Population

Anthony R Mato, MD, Andre Goy, MD, Kathryn Waksmundzki, BS, Tatyana Feldman, MD, Tania Zielonka, RDC, Ewelina A Protomastro, BA, Coleen Bejot, MSN, NP-C, Gabriella Gadaleta, RN, APN-C, Scott D Rowley, MD, Michele L Donato, MD, Andrew L Pecora, MD, Katherine Facchin, RN, John P. Leonard, MD, Richard R. Furman, MD, Jia Ruan, MD, PhD, Tsiporah B Shore, Usama Gergis, MD, Morton Coleman, MD, Rebecca Elstrom, MD
Journal: Blood
Blood (2012) 120 (21): 4269.
https://doi.org/10.1182/blood.V120.21.4269.4269
Published: 2012
Journal Articles

R-HCVAD/R-MTX-Arac (R-HCVAD) Overcomes Risk Features Associated with Inferior Outcomes In the Treatment of Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma (DLBCL).

Anthony R Mato, MD, Tatyana Feldman, MD, Tania Zielonka, Pritish K. Bhattacharyya, MD, Alexandria Campaiola, BSN, Rina P Shah, BA, Maria Rosario, Coleen Bejot, MSN, Susan Stives, MSN, Mary Curtin, MSN, Rosalba Vicioso, BA, Stuart L Goldberg, MD, Andrew L Pecora, MD, Andre Goy, MD
Journal: Blood
Blood (2010) 116 (21): 1782.
https://doi.org/10.1182/blood.V116.21.1782.1782
Published: 2010